Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe.
EQ-5D
Europe
FACT-H&N
First line treatment
Platinum-eligible
Quality of life
SCCHN
Squamous cell carcinoma of the head and neck
WPAI
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
24 Jul 2021
24 Jul 2021
Historique:
received:
29
03
2021
accepted:
03
06
2021
entrez:
25
7
2021
pubmed:
26
7
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Although current therapy for patients with early-stage squamous cell carcinoma of the head and neck (SCCHN) is potentially curative, the recurrence rate is high. Patients with recurrent or metastatic (R/M) SCCHN have a poor prognosis and substantial disease burden, including impaired health-related quality of life (HRQoL), productivity loss and indirect costs, such as need for caregiver support. The aim of this study was to characterize the impact of R/M SCCHN and its first-line treatment on patient and caregiver quality of life, daily activities and work productivity using real-world evidence from Europe. This was a multicentre retrospective study of patients with R/M SCCHN in France, Germany, Italy, Spain and the United Kingdom incorporating patient and caregiver surveys, and a physician-reported medical chart review, conducted between January and May 2019. Patients aged 18 or over with a physician confirmed diagnosis R/M SCCHN completed four validated measures of disease activity and its impact on quality of life and work productivity, while caregivers also completed questionnaire to assess the burden of providing care. Physicians provided data for clinical characteristics, patient management, testing history and treatment patterns. A total of 195 medical/clinical oncologists provided data for 937, predominantly male (72%) patients, with almost half of patients aged over 65 years. The most frequently reported symptoms were fatigue (43%), weight loss (40%), pain (35%) and difficulty swallowing (32%). The EXTREME regimen was the most common first line therapy in over half of patients, who reported moderate or extreme pain/discomfort, and anxiety/depression, and problems with self-care resulting in a diminished health status compared with the general population. Only 14% were employed with high absenteeism or presenteeism, and over half of patients had a caregiver for whom the burden of care was substantial. Our results provide real-world insight into the multi-faceted burden associated with R/M SCCHN. The combination of poor HRQoL and the impairment in daily activities, social life and employment illustrates the wider impact of R/M SCCHN on patients and their caregivers, and highlights a need for novel 1 L treatment regimens to improve the humanistic and productivity burdens of this cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Although current therapy for patients with early-stage squamous cell carcinoma of the head and neck (SCCHN) is potentially curative, the recurrence rate is high. Patients with recurrent or metastatic (R/M) SCCHN have a poor prognosis and substantial disease burden, including impaired health-related quality of life (HRQoL), productivity loss and indirect costs, such as need for caregiver support. The aim of this study was to characterize the impact of R/M SCCHN and its first-line treatment on patient and caregiver quality of life, daily activities and work productivity using real-world evidence from Europe.
METHODS
METHODS
This was a multicentre retrospective study of patients with R/M SCCHN in France, Germany, Italy, Spain and the United Kingdom incorporating patient and caregiver surveys, and a physician-reported medical chart review, conducted between January and May 2019. Patients aged 18 or over with a physician confirmed diagnosis R/M SCCHN completed four validated measures of disease activity and its impact on quality of life and work productivity, while caregivers also completed questionnaire to assess the burden of providing care. Physicians provided data for clinical characteristics, patient management, testing history and treatment patterns.
RESULTS
RESULTS
A total of 195 medical/clinical oncologists provided data for 937, predominantly male (72%) patients, with almost half of patients aged over 65 years. The most frequently reported symptoms were fatigue (43%), weight loss (40%), pain (35%) and difficulty swallowing (32%). The EXTREME regimen was the most common first line therapy in over half of patients, who reported moderate or extreme pain/discomfort, and anxiety/depression, and problems with self-care resulting in a diminished health status compared with the general population. Only 14% were employed with high absenteeism or presenteeism, and over half of patients had a caregiver for whom the burden of care was substantial.
CONCLUSION
CONCLUSIONS
Our results provide real-world insight into the multi-faceted burden associated with R/M SCCHN. The combination of poor HRQoL and the impairment in daily activities, social life and employment illustrates the wider impact of R/M SCCHN on patients and their caregivers, and highlights a need for novel 1 L treatment regimens to improve the humanistic and productivity burdens of this cancer.
Identifiants
pubmed: 34303346
doi: 10.1186/s12885-021-08557-2
pii: 10.1186/s12885-021-08557-2
pmc: PMC8310582
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
854Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2016 Aug 20;34(24):2925-34
pubmed: 27247218
J Manag Care Spec Pharm. 2017 Feb;23(2):136-162
pubmed: 28125370
Arch Otolaryngol Head Neck Surg. 1996 May;122(5):482-7
pubmed: 8615964
Cancer. 2014 Sep 15;120(18):2902-9
pubmed: 24853866
Health Qual Life Outcomes. 2008 Nov 07;6:94
pubmed: 18992139
Pharmacoeconomics. 2014 Sep;32(9):865-82
pubmed: 24842794
Front Oncol. 2017 May 09;7:72
pubmed: 28536670
Appl Health Econ Health Policy. 2015 Aug;13(4):359-67
pubmed: 25691128
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
Oral Oncol. 2016 Jan;52:18-23
pubmed: 26578389
Surg Oncol Clin N Am. 2018 Oct;27(4):675-684
pubmed: 30213412
Head Neck. 2013 Sep;35(9):1331-8
pubmed: 22907791
Cancer. 2015 Mar 1;121(5):766-73
pubmed: 25369213
Aging Ment Health. 2006 Mar;10(2):107-11
pubmed: 16517485
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Eval Health Prof. 2005 Jun;28(2):192-211
pubmed: 15851773
Value Health. 2012 May;15(3):429-36
pubmed: 22583452
Psychooncology. 2017 Feb;26(2):149-160
pubmed: 26918648
J Patient Rep Outcomes. 2018 Dec 13;2(1):62
pubmed: 30547275
Qual Life Res. 2004 May;13(4):725-33
pubmed: 15129883
Oral Oncol. 2010 Jan;46(1):56-60
pubmed: 20004135
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Adv Clin Exp Med. 2014 Nov-Dec;23(6):1019-27
pubmed: 25618131
Front Oncol. 2019 May 20;9:383
pubmed: 31165040
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Cancer. 1996 Jun 1;77(11):2294-301
pubmed: 8635098
Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862
pubmed: 29927010
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669
J Cancer Surviv. 2008 Sep;2(3):149-58
pubmed: 18792789
Cancer. 2016 Jun 15;122(12):1861-70
pubmed: 27182694
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
Gerontologist. 2001 Oct;41(5):652-7
pubmed: 11574710